1-2 of 2
Douglas Clark
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Christoph Wanner, Uwe Hehnke, Isabella Zwiener, Stefan Kaspers, Douglas Clark, Jyothis T. George, Bernard Zinman
Journal: Diabetes Care
Diabetes Care 2019;42(4):e53–e55
https://doi.org/10.2337/dc18-1355
Published: 31 January 2019
View article titled, Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
Open the PDF for Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial in another window
Journal Articles

Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting

Shoko Maru, DSC, Gary G. Koch, PHD, Monika Stender, DRSCHUM, Douglas Clark, MBA, Laura Gibowski, MPH, Hans Petri, MD, PHD, Alice D. White, PHD, Ross J. Simpson, Jr., MD, PHD
Journal: Diabetes Care
Diabetes Care 2005;28(1):20–26
https://doi.org/10.2337/diacare.28.1.20
Published: 01 January 2005
View article titled, Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting
Open the PDF for Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting in another window